Ambristar 5 Tablets provide an established, clinically unified cardiovascular and pulmonary therapy carefully developed for the continuous management, long-term stabilization, and symptom optimization of patients navigating Pulmonary Arterial Hypertension (PAH). In progressive pulmonary vascular diseases, an excessive localized production of endothelin (a highly potent natural vasoconstrictor peptide) forces the smooth muscle walls of the pulmonary arteries into rigid, continuous contraction. This sustained structural tightening narrows blood pathways, forces pulmonary arterial pressure lines to dangerous heights, and subjects the right ventricle of the heart to exhausting mechanical stress. This advanced formulation delivers a selective, targeted receptor blocker within a standard 5 mg unit to restore healthy, expanded pulmonary vascular fields safely over a daily chronic routine.
The active component, Ambrisentan (5 mg), functions dynamically via highly targeted molecular tracks:
-
Selective Endothelin Type-A ($\text{ET}_\text{A}$) Antagonism: It operates as a high-affinity, selective antagonist of the endothelin type-A ($\text{ET}_\text{A}$) receptor subtype localized predominantly on vascular smooth muscle cells. By tightly locking these receptors, it completely blocks the powerful vasoconstrictive and tissue-proliferative signals triggered by circulating endothelin-1 peptides.
-
Preservation of Endothelin Type-B ($\text{ET}_\text{B}$) Function: Unlike non-selective agents, its high selectivity spares the endothelin type-B ($\text{ET}_\text{B}$) receptors located on endothelial cells. Maintaining functional $\text{ET}_\text{B}$ pathways supports the beneficial, localized synthesis of vasodilating nitric oxide and prostacyclin while assisting in the natural cellular clearance of excess endothelin from the bloodstream around the clock.
Key Benefits
-
Targeted Pulmonary Vasodilation: Selectively opens narrowing blood channels directly within the lung fields to re-establish smooth, unrestricted blood velocity.
-
Stamina & Exercise Capacity Booster: Markedly expands physical tolerance limits, helping to lower daily fatigue and shortness of breath during routing activities.
-
Cardiac Workload Decompression: Drops high upstream pulmonary resistance, preventing cellular stretching and right-sided heart failure complications.
-
Highly Selective Profile Safety: Targeted receptor affinity profile optimizes therapeutic efficacy while reducing the statistical tracking rates of acute liver enzyme flaring.
-
Trusted Quality Management: Manufactured under strict pharmaceutical protocols of Steris, ensuring absolute dosage uniformity and exceptional active core stability.
Directions for Use
-
Take exactly as directed by your pulmonologist, cardiologist, or primary care specialist.
-
Ambristar 5 is strictly administered as a single tablet once daily, at the exact same hour every single day.
-
Can be taken comfortably either with or without food. Maintaining an identical daily hour is critical to secure a perfectly flat, uninterrupted 24-hour plasma tracking baseline.
-
Swallow the tablet whole with a full glass of plain water. Do not crush, break, split, or chew it.
Safety & Precautions
-
CRITICAL EMBRYO-FETAL TOXICITY WARNING: Ambristar 5 must strictly never be used during pregnancy. Ambrisentan can cause severe, life-threatening birth defects if administered to a pregnant woman. Female patients of reproductive potential must verify a negative pregnancy test prior to starting therapy, use highly reliable, dual-contraception tracking methods continuously throughout use, and undergo routine monthly pregnancy screenings under strict specialist surveillance.
-
Fluid Retention & Edema Rule: This class of medication can prompt systemic fluid buildup, leading to peripheral edema (swelling of ankles and feet). Monitor your weight closely and notify your specialist immediately if you experience rapid, unexplained weight gain or sudden worsening of breathing difficulties.
-
Hemoglobin Tracking Parameter: Ambrisentan can cause a minor drop in hemoglobin levels and red blood cell counts during early titration. Regular blood count profiles (CBC / Hemoglobin) are recommended during initiation.
-
Inform your specialist before initialization if you track a prior clinical record of severe liver impairment, significant pulmonary veno-occlusive disease, or advanced fluid congestion.
-
Keep out of reach of children.
Storage
-
Store in a cool, dry place below 30°C.
-
Protect from direct sunlight, excessive heat sources, and environmental room moisture pools.
-
Always keep the pink tablets safely sealed inside their original protective blister packaging layout until the exact moment of intake to shield the core components from ambient humidity degradation.
